However, some studies have found that DNMT3A mutations in AML patients affect patient prognosis and are negatively associated with patient prognosis (6, 7), and this adverse prognostic effect may be limited to specific types of AML groups (8–11). This evidence concerns the gene DNMT3A and acute myeloid leukemia.